Cargando…

A nationwide study of the epidemiology of relapsing polychondritis

OBJECTIVE: Relapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Horváth, Anna, Páll, Nóra, Molnár, Katalin, Kováts, Tamás, Surján, György, Vicsek, Tamás, Pollner, Péter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934462/
https://www.ncbi.nlm.nih.gov/pubmed/27418855
http://dx.doi.org/10.2147/CLEP.S91439
_version_ 1782441338983153664
author Horváth, Anna
Páll, Nóra
Molnár, Katalin
Kováts, Tamás
Surján, György
Vicsek, Tamás
Pollner, Péter
author_facet Horváth, Anna
Páll, Nóra
Molnár, Katalin
Kováts, Tamás
Surján, György
Vicsek, Tamás
Pollner, Péter
author_sort Horváth, Anna
collection PubMed
description OBJECTIVE: Relapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and associations of this highly variable disease by collecting all cases from a 124-million-person-year Central European nationwide cohort. METHODS: We used the Hungarian Health Care Database to identify all persons with possible RP infection. We followed patients who had International Classification of Diseases 10th edition code M94.1 at least once in their inpatient or outpatient records between January 1, 2002 and December 31, 2013 in Hungary. We classified these patients into disease severity groups by their drug consumption patterns between January 1, 2010 and December 31, 2013. We analyzed the regional distribution of RP incidences as well. Overall maps of comorbidity are presented with network layouts. RESULTS: We identified 256 patients with RP among cumulatively 11.5 million registered inhabitants. We classified these patients into four severity classes as “extremely mild” (n=144), “mild” (n=22), “moderate” (n=41), and “severe” (n=4). Two additional groups were defined for patients without available drug data as “suspected only” (n=23) and “confirmed but unknown treatment” (n=22). The age and sex distributions of patients were similar to worldwide statistics. Indeed, the overall survival was good (95% confidence interval for 5 years was 83.6%–92.9% and for 10 years was 75.0%–88.3% which corresponds to the overall survival of the general population in Hungary), and the associations with other autoimmune disorders were high (56%) in Hungary. Almost any disease can occur with RP; however, the symptoms of chromosomal abnormalities are only incidental. Spondylosis can be a sign of the activation of RP, while Sjögren syndrome is the most frequent autoimmune association. Regional distribution of incidences suggests arsenic drinking water and sunlight exposure as possible triggering factors. CONCLUSION: The good survival rate of RP in Hungary is probably associated with the early diagnosis of the disease.
format Online
Article
Text
id pubmed-4934462
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49344622016-07-14 A nationwide study of the epidemiology of relapsing polychondritis Horváth, Anna Páll, Nóra Molnár, Katalin Kováts, Tamás Surján, György Vicsek, Tamás Pollner, Péter Clin Epidemiol Original Research OBJECTIVE: Relapsing polychondritis (RP) is a rare autoimmune inflammatory disease that attacks mainly cartilaginous structures or causes serious damage in proteoglycan-rich structures (the eyes, heart, blood vessels, inner ear). This study shows results regarding the epidemiology, progression, and associations of this highly variable disease by collecting all cases from a 124-million-person-year Central European nationwide cohort. METHODS: We used the Hungarian Health Care Database to identify all persons with possible RP infection. We followed patients who had International Classification of Diseases 10th edition code M94.1 at least once in their inpatient or outpatient records between January 1, 2002 and December 31, 2013 in Hungary. We classified these patients into disease severity groups by their drug consumption patterns between January 1, 2010 and December 31, 2013. We analyzed the regional distribution of RP incidences as well. Overall maps of comorbidity are presented with network layouts. RESULTS: We identified 256 patients with RP among cumulatively 11.5 million registered inhabitants. We classified these patients into four severity classes as “extremely mild” (n=144), “mild” (n=22), “moderate” (n=41), and “severe” (n=4). Two additional groups were defined for patients without available drug data as “suspected only” (n=23) and “confirmed but unknown treatment” (n=22). The age and sex distributions of patients were similar to worldwide statistics. Indeed, the overall survival was good (95% confidence interval for 5 years was 83.6%–92.9% and for 10 years was 75.0%–88.3% which corresponds to the overall survival of the general population in Hungary), and the associations with other autoimmune disorders were high (56%) in Hungary. Almost any disease can occur with RP; however, the symptoms of chromosomal abnormalities are only incidental. Spondylosis can be a sign of the activation of RP, while Sjögren syndrome is the most frequent autoimmune association. Regional distribution of incidences suggests arsenic drinking water and sunlight exposure as possible triggering factors. CONCLUSION: The good survival rate of RP in Hungary is probably associated with the early diagnosis of the disease. Dove Medical Press 2016-06-23 /pmc/articles/PMC4934462/ /pubmed/27418855 http://dx.doi.org/10.2147/CLEP.S91439 Text en © 2016 Horváth et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Horváth, Anna
Páll, Nóra
Molnár, Katalin
Kováts, Tamás
Surján, György
Vicsek, Tamás
Pollner, Péter
A nationwide study of the epidemiology of relapsing polychondritis
title A nationwide study of the epidemiology of relapsing polychondritis
title_full A nationwide study of the epidemiology of relapsing polychondritis
title_fullStr A nationwide study of the epidemiology of relapsing polychondritis
title_full_unstemmed A nationwide study of the epidemiology of relapsing polychondritis
title_short A nationwide study of the epidemiology of relapsing polychondritis
title_sort nationwide study of the epidemiology of relapsing polychondritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934462/
https://www.ncbi.nlm.nih.gov/pubmed/27418855
http://dx.doi.org/10.2147/CLEP.S91439
work_keys_str_mv AT horvathanna anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT pallnora anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT molnarkatalin anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT kovatstamas anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT surjangyorgy anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT vicsektamas anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT pollnerpeter anationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT horvathanna nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT pallnora nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT molnarkatalin nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT kovatstamas nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT surjangyorgy nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT vicsektamas nationwidestudyoftheepidemiologyofrelapsingpolychondritis
AT pollnerpeter nationwidestudyoftheepidemiologyofrelapsingpolychondritis